A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Empirical and theoretical approaches pioneered by CRA economists have been accepted as standard practice by competition economists and enforcers worldwide.
We tailor our analyses to fit the facts and economics of each case, bringing a unique combination of creativity and rigor to each matter. CRA economists have also testified in litigated competition cases, or met with and provided submissions to antitrust enforcement agencies. In our work, and in discussions with clients, we distill complex competition issues and economic analyses into concepts and arguments that are understandable to non-economists.
Our expertise in antitrust economics, econometrics, mergers, acquisitions, divestitures, and related matters has made us the firm of choice for clients and competition authorities around the globe. Our globally based antitrust economists have the knowledge, jurisdiction-specific expertise, and geographic presence required to efficiently support clients around the world.
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...
Isabel Tecu is the moderator of the first installment of Groundbreakers, a new economics seminar series by the ABA Antitrust Section Econ Committee, featuring...
CRA is a proud sponsor of the event. Oli Latham is a panelist during the session titled “The Digital Markets, Competition and Consumers Act: From Adoption to...
Benno Buehler is a panelist during the session titled “Challenges to FRAND rate setting – negotiation v. litigation.” For more information on this event, click...
Peter Boberg, Sandra Chan, Matt List and Sean May present the Health Care & Pharmaceutical Committee’s quarterly update, summarizing the most important...